METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets Hard-to-Treat breast cancer in early trial
Disease control TerminatedThis phase I trial is testing a new drug called ASTX727 (a combination of decitabine and cedazuridine) alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The st…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise against tough breast cancer
Disease control OngoingThis study tests a combination of two drugs, eribulin and copanlisib, in people with metastatic triple-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combo can slow tumor growth better than eribulin alone. About 24 …
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could estrogen shrink some triple negative breast tumors?
Disease control OngoingThis phase II trial at Mayo Clinic tests whether estradiol, a form of estrogen, can help patients with a specific subtype of triple negative breast cancer that has a receptor called ER beta. The study enrolls 8 women with advanced or metastatic disease. Researchers will measure h…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Cancer-Killing virus trial launches for Hard-to-Treat breast cancer
Disease control OngoingThis early-phase trial tests a new treatment for metastatic triple-negative breast cancer, a type that has spread and is hard to treat. The treatment uses a specially designed virus that is injected directly into tumors to infect and destroy cancer cells. The main goal is to find…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo therapy aims to boost immune attack on hard-to-treat cancers
Disease control OngoingThis early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…
Matched conditions: METASTATIC TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC